Security Class Suspension from Quotation CHMO
Filed with ASX · · 1 page · English
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Final Results in Phase 1 Trial of CORE NK Platform
- Chimeric partners with Be the Match BioTherapies
- Successful completion of Institutional Entitlement Offer
- Entitlement Offer to raise approximately $18.1 million
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
Later from Chimeric Therapeutics
- Completion of retail component of Entitlement Offer
- CDH17 CAR t preclinical data featured in Nature Cancer
- Security Class Reinstatement to Quotation CHMO
- Strategic manufacturing partnership with WuXi ATU
- A$30 million Equity Placement Agreement with L1 Capital
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics